Royalty Pharma plcRPRXEarnings & Financial Report
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
Revenue
$578.7M
Gross Profit
N/A
Operating Profit
$209.8M
Net Profit
$30.2M
Gross Margin
N/A
Operating Margin
36.3%
Net Margin
5.2%
YoY Growth
7.7%
EPS
$0.07
Royalty Pharma plc Q2 FY2025 Financial Summary
Royalty Pharma plc reported revenue of $578.7M (up 7.7% YoY) for Q2 FY2025, with a net profit of $30.2M (down 70.4% YoY) (5.2% margin).
Key Financial Metrics
| Total Revenue | $578.7M |
|---|---|
| Net Profit | $30.2M |
| Gross Margin | N/A |
| Operating Margin | 36.3% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
Royalty Pharma plc Q2 FY2025 revenue of $578.7M breaks down across 2 segments, led by Financial Royalty Assets at $550.4M (95.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Financial Royalty Assets | $550.4M | 95.1% |
| Royalty Income Other | $28.2M | 4.9% |
Royalty Pharma plc Revenue by Segment — Quarterly Trend
Royalty Pharma plc revenue by segment across the last 4 reported quarters, showing how each business line (such as Financial Royalty Assets and Royalty Income Other) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Financial Royalty Assets | $592.4M | $578.8M | $550.4M | $539.5M |
| Royalty Income Other | $29.6M | $30.5M | $28.2M | $28.8M |
Royalty Pharma plc Annual Revenue by Year
Royalty Pharma plc annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.4B).
| Year | Annual Revenue |
|---|---|
| 2025 | $2.4B |
| 2024 | $2.3B |
| 2023 | $2.4B |
| 2022 | $2.2B |
Royalty Pharma plc Quarterly Revenue & Net Profit History
Royalty Pharma plc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $622.0M | +4.8% | $214.2M | 34.4% |
| Q3 FY2025 | $609.3M | +7.9% | $288.2M | 47.3% |
| Q2 FY2025 | $578.7M | +7.7% | $30.2M | 5.2% |
| Q1 FY2025 | $568.2M | +0.0% | $238.3M | 41.9% |
| Q4 FY2024 | $593.6M | -0.4% | $208.2M | 35.1% |
| Q3 FY2024 | $564.7M | +5.3% | $544.0M | 96.3% |
| Q2 FY2024 | $537.3M | -0.2% | $102.0M | 19.0% |
| Q1 FY2024 | $568.0M | -17.0% | $4.8M | 0.8% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $568.0M | $537.3M | $564.7M | $593.6M | $568.2M | $578.7M | $609.3M | $622.0M |
| YoY Growth | -17.0% | -0.2% | 5.3% | -0.4% | 0.0% | 7.7% | 7.9% | 4.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $16.13B | $17.66B | $18.04B | $18.22B | $17.61B | $18.32B | $19.35B | $19.62B |
| Liabilities | $6.27B | $7.90B | $7.78B | $7.88B | $7.82B | $8.82B | $9.73B | $9.91B |
| Equity | $9.86B | $9.75B | $10.26B | $10.34B | $9.79B | $9.50B | $9.62B | $9.71B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $664.6M | $658.2M | $703.6M | $742.5M | $596.1M | $364.0M | $702.6M | $827.1M |